Simultaneous detection and epitope mapping of anti-factor VIII antibodies

Thrombosis and Haemostasis

Volumn 99, Issue 6, 2008, Pages 1090-1096

  Lavigne Lissalde, Géraldine ^a,b,c   Tarrade, Catherine ^a   Lapalud, Priscilla ^a   Chtourou, Sami ^d   Schved, Jean François ^c   Granier, Claude ^a   Villard Saussine, Sylvie ^a  

^a CNRS   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c HÔPITAL SAINT ELOI   (France)

^d LFB Biotechnologies   (France)

Author keywords

Epitope mapping; Haemophilia A; Inhibitors

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; MONOCLONAL ANTIBODY; PHYCOERYTHRIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; HEMOPHILIA A; HUMAN; IMMOBILIZATION; PRIORITY JOURNAL; SCREENING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; EPITOPE MAPPING; FACTOR VIII; FEASIBILITY STUDIES; FRANCE; HEMOPHILIA A; HUMANS; IMMUNOASSAY; ISOANTIBODIES; MICE; SWITZERLAND;

EID: 44949119714     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-08-0497     Document Type: Article

References (37)

1. Lavigne-Lissalde G, et al. Anti-factor VIII antibodies: a 2005 update. Thromb Haemost 2005; 94: 760-769.
2. Ehrenforth S, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
3. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
4. Kasper CK, Pool JG. Measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh 1975; 34: 875-876.
5. Kazatchkine MD, et al. Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A. Clin Exp Immunol 1980; 39: 315-320.
6. Sahud MA, et al. ELISA system for Detection of Immune Responses to Factor VIII: a study of 246 samples and correlation with the Bethesda assay. Hemophilia 2007; 13: 317-322.
7. Towfighi F, et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84-90.
8. Shetty S, et al. ELISA for factor VIII antibodies: does it detect antibodies much before the conventional Bethesda assay? Haemophilia 2003; 9: 654.
9. Martin PG, et al. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999; 21: 125-128.
10. Wight J, et al. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 436-463.
11. Collins PW. Novel therapies for immune tolerance in haemophilia A. Haemophilia 2006; 12: 94-101.
12. Dimichele DM. Management of factor VIII inhibitors. Int J Hematol 2006; 83: 119-125.
13. Acharya SS, DiMichele DM. Management of factor VIII inhibitors. Best Pract Res Clin Haematol 2006; 19: 51-66.
14. Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
15. Auerswald G, et al. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
16. Kreuz W, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
17. Orsini F, et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-1290.
18. Gringeri A, et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-379.
19. Greninger DA, et al. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; in print.
20. Kurth MA, et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-55.
21. Waterboer T, et al. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006; 309: 200-204.
22. Fulton RJ, et al. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 1997; 43: 1749-1756.
23. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 1997; 272: 18007-18014.
24. Lavigne-Lissalde G, et al. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice. Thromb Haemost 2007; 98: 138-147.
25. Jacquemin MG, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
26. Giles AR, et al. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-875.
27. Kessler CM. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future. Haematologica 2000; 85: 57-61.
28. Dimichele D. Factor VIII pharmacokinetics: impact of low titer non-neutralizing inhibitors and use in determination of successful immune tolerance. Haemophilia 2006; 12: 56-60.
29. Lollar P. Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematologica 2000; 85: 26-28.
30. Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang 1996; 70: 9-14.
31. Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sang 1999; 77: 17-20.
32. Collins PW, et al. Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors' Organisation. Blood 2006; 105: 1870-1877.
33. Bray GL, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-2435.
34. Fischer K, et al. Dose and outcome of care in haemophilia - how do we define cost-effectiveness? Haemophilia 2004; 10: 216-220.
35. Fulcher CA, et al. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 1988; 72: 1348-1356.
36. Shima M. Characterization of factor VIII inhibitors. Int J Haematol 2006; 83: 109-118.
37. Prescott R, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-3671.